載入...
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
BACKGROUND: In patients with Philadelphia-positive acute lymphoblastic leukemia, resistance to treatment with tyrosine kinase inhibitors is frequent and most often associated with the development of point mutations in the BCR-ABL kinase domain. We aimed to assess: (i) in how many patients BCR-ABL ki...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Ferrata Storti Foundation
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3069232/ https://ncbi.nlm.nih.gov/pubmed/21193419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.034173 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|